Durability of glycemic control using U-500 insulin

详细信息	查看全文 | 推荐本文 |

• 作者：Alexandria M. Dailey^a ; Jennifer A. Gibert^b ; Lisa R. Tannock^b ; ^c ; ^{lisa.tannock@uky.edu}
• 关键词：Insulin resistance ; HbA1c ; Weight gain ; Hypoglycemia
• 刊名：Diabetes Research and Clinical Practice
• 出版年：2012
• 期刊代码：78_01688227
• 类别：med
• 出版时间：March, 2012
• 卷：95
• 期：3
• 页码：340-344
• 文件大小：280 K

摘要

Previous short-term studies evaluating U-500 insulin have reported improvements in glycemic control but with significant weight gain. This study was performed to examine the glycemic durability of U-500 insulin in highly insulin resistant subjects, and to determine if weight gain was continuous with use. Patients using U-500 insulin provided consent for chart reviews for up to 3 years prior to and 3 years after use of U-500 insulin. Charts were reviewed for physical and metabolic data from 53 subjects using U-500 insulin of which 20 used U-500 insulin for 3 years. Use of U-500 insulin led to an approximate 1%decrease in HbA1c within 3-6 months of use which was sustained for up to 3 years. Patients required increased insulin doses (by 鈭?0%) over the first 6-12 months with a corresponding weight gain (鈭?0 lbs) and a spike in hypoglycemia symptoms, but then insulin doses and body weight, as well as glycemic control and hypoglycemic symptoms, stabilized over subsequent follow up. Use of U-500 insulin in a clinical diabetes practice leads to sustained improvements in glycemic control following a period of insulin titration and weight gain. Despite the weight gain, glycemic control was sustained for up to 3 years.